0P6S.LSE Bayer AG NA
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0P6S.LSE undervalued?
Graham numberThe Graham number of Bayer AG NA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bayer AG NA fundamental analysis
No fundamental analysis for Bayer AG NA yet.
Bayer AG NA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and d…
Full company profileBayer AG NA financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bayer AG NA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 34.9B | 35.0B | 36.7B | 43.5B | 41.4B | - | - | - |
| Gross Profit | 23.2B | 23.6B | 21.4B | 25.9B | 22.3B | - | - | - |
| Operating Income | 5.74B | 5.90B | 3.45B | 4.16B | -16.2B | - | - | - |
| Net Income | 4.53B | 7.34B | 1.70B | 4.09B | -10.5B | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 82.2B | 75.1B | 127B | 126B | 117B | - | - | - |
| Total Liabilities | 51.9B | 38.3B | 80.8B | 78.9B | 86.2B | - | - | - |
| Shareholders' Equity | 30.3B | 36.8B | 46.0B | 47.3B | 30.5B | - | - | - |
| Cash & Short-term Investments | 5.42B | 9.10B | 5.00B | 5.40B | 12.1B | - | - | - |
| Total Debt | 15.4B | 12.2B | 37.7B | 36.9B | 33.2B | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 9.09B | 8.13B | 7.92B | 8.21B | 4.90B | 5.09B | 7.09B | - |
| Capital Expenditure | 2.58B | 2.37B | 2.59B | 2.65B | 2.42B | 2.61B | 2.95B | 0.00 |
| Ratios | ||||||||
| ROE | 14.9% | 19.9% | 3.7% | 8.7% | -34.4% | - | - | - |
| ROA | 5.5% | 9.8% | 1.3% | 3.2% | -9.0% | - | - | - |
| Net Profit Margin | 13.0% | 21.0% | 4.6% | 9.4% | -25.4% | - | - | - |
| Debt to Equity | 0.51x | 0.33x | 0.82x | 0.78x | 1.09x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bayer AG NA dividends
Bayer AG NA has not paid dividends in the last 9 fiscal years.
Last stock split: 10:1 on Jun 3, 1996.
Who owns Bayer AG NA
- Insiders 0.01%
- Institutions 62.18%
- Public & others 37.81%
- Free float 982M
Bayer AG NA company profile
- Company name
- Bayer AG NA
- Ticker
- 0P6S.LSE
- ISIN
- DE000BAY0017
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87,830
- Fiscal year end
- December
- Address
- Kaiser-Wilhelm-Allee 1, Leverkusen, Germany, 51368
- Phone
- 49 214 30 1
- Website
- bayer.com
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Bayer AG NA management
10- Mr. William N. AndersonChairman of the Management Board & CEO · born 1966
- Mr. Stefan OelrichPresident of the Pharmaceuticals Division & Member of the Board of Management · born 1968
- Ms. Heike PrinzChief Talent Officer, Labor Director & Member of Management Board · born 1964
- Dr. Judith HartmannCFO & Member of Management Board · born 1969
- Mr. Rodrigo SantosMember of Management Board, Head of the Crop Science Division & President of Crop Science Division · born 1973
- Mr. Julio TrianaMember of Management Board & President of Consumer Health Division · born 1965
- Mr. Alex BuschermohleChief Information Officer, Head-Digital Transformation & IT-Crop Science Division
- Ms. Jana Marlen AckermannHead of the Investor Relations · born 1984
- Mr. Bill DoderoGeneral Counsel and Senior VP of Law Patents & Compliance
- Mr. Michael PreussHead of Communications, Government Relations and Corporate Brand